Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx “Plan B”: Rep. Burton Chairs First Public Discussion On Fallback

Executive Summary

Alternatives to passing a full Medicare prescription drug benefit will be given their first public airing since the Medicare conference committee was formed when the House Government Reform/Human Rights & Wellness Subcommittee convenes for a hearing Sept. 24

You may also be interested in...



Reimportation Survey Demonstrates Rx Industry’s Public Relations Challenge

Pharmaceutical companies' opposition to importing drugs from Canada into the U.S. is "unreasonable," according to a survey of Americans released Oct. 9

Reimportation Survey Demonstrates Rx Industry’s Public Relations Challenge

Pharmaceutical companies' opposition to importing drugs from Canada into the U.S. is "unreasonable," according to a survey of Americans released Oct. 9

Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay

Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel